MiR-320 is currently considered as a potential target for type 2 diabetes mellitus therapy (34, 35) since it regulates the expression of phosphoinositide-3-kinase (PI3K), a downstream mediator of insulin signaling. This evidence concerns the gene INS and diabetes mellitus.